283 related articles for article (PubMed ID: 37435267)
21. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
23. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
24. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
25. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
[TBL] [Abstract][Full Text] [Related]
26. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
[TBL] [Abstract][Full Text] [Related]
27. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.
Punekar YS; Guo N; Tremblay G; Piercy J; Holbrook T; Young B
Cost Eff Resour Alloc; 2019; 17():26. PubMed ID: 31827410
[TBL] [Abstract][Full Text] [Related]
28. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
29. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
[No Abstract] [Full Text] [Related]
31. Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Li M; Cao Y; Huang H; Qin G; Chu M; Zou M; Zhuang X
BMC Public Health; 2023 Nov; 23(1):2228. PubMed ID: 37953277
[TBL] [Abstract][Full Text] [Related]
32. Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials.
Shu Y; Deng Z; Wang H; Chen Y; Yuan L; Deng Y; Tu X; Zhao X; Shi Z; Huang M; Qiu C
AIDS Res Ther; 2021 May; 18(1):25. PubMed ID: 33933131
[TBL] [Abstract][Full Text] [Related]
33. Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.
Dumchev K; Kiriazova T; Riabokon S; Shost A; Parrish C; Shapoval A; Germanovych M; Penner J; Beste J; Puttkammer N
J Acquir Immune Defic Syndr; 2022 Oct; 91(2):197-209. PubMed ID: 36094487
[TBL] [Abstract][Full Text] [Related]
34. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
Infect Dis Ther; 2023 Mar; 12(3):843-861. PubMed ID: 36520332
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
[TBL] [Abstract][Full Text] [Related]
37. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study.
Jemal M; Shibabaw Molla T; Tiruneh G Medhin M; Chekol Abebe E; Asmamaw Dejenie T
Ann Med; 2023; 55(2):2295435. PubMed ID: 38118463
[TBL] [Abstract][Full Text] [Related]
38. Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil.
Mendes JC; Braga MDG; Reis AMM; Silveira MR
Curr Med Res Opin; 2023 Apr; 39(4):523-531. PubMed ID: 36912019
[TBL] [Abstract][Full Text] [Related]
39. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
